Trials / Completed
CompletedNCT01053819
Can We Miss Pigmented Lesions in Psoriasis Patients?
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions. However, successful systemic treatment and subsequent clearing of psoriatic plaques may allow clinicians to better evaluate pigmented lesions, thereby increasing the likelihood of early identification and treatment of suspicious lesions such as nonmelanoma skin cancer and malignant melanoma.
Detailed description
No further description is desired.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | etanercept | Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter. |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2010-01-21
- Last updated
- 2018-02-23
- Results posted
- 2012-08-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01053819. Inclusion in this directory is not an endorsement.